Amyloid deposition is decreasing in aging brains : An autopsy study of 1,599 older people

Neurology

Volumn 82, Issue 4, 2014, Pages 326-331

  Kövari, Enikö ^a   Herrmann, François R ^b   Bouras, Constantin ^a   Gold, Gabriel ^b  

^a Departments of Mental Health and Psychiatry Internal Medicine   (Switzerland)

^b University of GenevaMedical School and University Hospitals   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; COGNITION; DEATH; DEMENTIA; DISEASE SEVERITY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; AMYLOID; AUTOPSY; BRAIN; COHORT STUDIES; FEMALE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; REGRESSION ANALYSIS;

EID: 84895746988     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000069     Document Type: Article

References (41)

1. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169-175.
2. Frisoni GB. Alzheimer disease: Biomarker trajectories across stages of Alzheimer disease. Nat Rev Neurol 2012;8:299-300.
3. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-1465.
4. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDSADRDA criteria. Lancet Neurol 2007;6:734-746.
5. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42: 631-639.
6. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 2004;61:378-384.
7. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995;16:271-278.
8. Dowling NM, Tomaszewski Farias S, Reed BR, et al. Neuropathological associates of multiple cognitive functions in two community-based cohorts of older adults. J Int Neuropsychol Soc 2010;17:602-614.
9. Giannakopoulos P, Herrmann FR, Bussière T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003; 60:1495-1500.
10. Gold G, Kövari E, Corte G, et al. Clinical validity of A b-protein deposition staging in brain aging and Alzheimer disease. J Neuropathol Exp Neurol 2001;60:946-952.
11. Grober E, Dickson D, Sliwinski MJ, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging 1999;20:573-579.
12. Nelson PT, Jicha GA, Schmitt FA, et al. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: Neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol 2007;66:1136-1146.
13. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004;62:1984-1989.
14. Gold G, Bouras C, Kövari E, et al. Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol 2000;99:579-582.
15. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991;1:213-216.
16. Braak H, Braak E. Frequency of stages of Alzheimerrelated lesions in different age categories. Neurobiol Aging 1997;18:351-357.
17. Iqbal K, Braak E, Braak H, Zaidi T, Grundke-Iqbal I. A silver impregnation method for labeling both Alzheimer paired helical filaments and their polypeptides separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Neurobiol Aging 1991;12:357-361.
18. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82: 239-259.
19. Thal DR, Rüb U, Orantes M, Braak H. Phases of Abdeposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
20. Guo Z, Viitanen M, Fratiglioni L, Winblad B. Low blood pressure and dementia in elderly people: The Kungsholmen project. BMJ 1996;312:805-808.
21. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347: 1141-1145.
22. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target g-secretase and lower Ab 42 in vivo. J Clin Invest 2003;112:440-449.
23. Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's b-amyloid fibrils in vitro. Neuropharmacology 2005;49:1088-1099.
24. Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci 2010;2:19.
25. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 2000;7:312-321.
26. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000;20:5709-5714.
27. McKee AC, Carreras I, Hossain L, et al. Ibuprofen reduces Ab, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008;1207:225-236.
28. Sung S, Yang H, Uryu K, et al. Modulation of nuclear factor-kappa B activity by indomethacin influences Ab levels but not Ab precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 2004;165:2197-2206.
29. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Ab42 independently of cyclooxygenase activity. Nature 2001;414:212-216.
30. Weggen S, Eriksen JL, Sagi SA, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid b 42 production by direct modulation of g-secretase activity. J Biol Chem 2003;278:31831-31837.
31. Weggen S, Rogers M, Eriksen J. NSAIDs: Small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci 2007; 28:536-543.
32. Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy alters b-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003;23: 7504-7509.
33. Fonseca AC, Resende R, Oliveira CR, Pereira CM. Cholesterol and statins in Alzheimer's disease: Current controversies. Exp Neurol 2010;223:282-293.
34. Kirsch C, Eckert GP, Koudinov AR, Muller WE. Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry 2003;36(suppl 2):S113-S119.
35. Kurata T, Miyazaki K, Kozuki M, et al. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. Neurol Res 2012;34:601-610.
36. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-b production through inhibition of protein isoprenylation. J Biol Chem 2007;282: 26832-26844.
37. Won JS, Im YB, Khan M, Contreras M, Singh AK, Singh I. Lovastatin inhibits amyloid precursor protein (APP) b-cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. J Neurochem 2008;105:1536-1549.
38. Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992;256:184-185.
39. Qiu C, von Strauss E, Backman L,Winblad B, Fratiglioni L. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013; 80:1888-1894.
40. Rocca WA, Petersen RC, Knopman DS, et al. Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States. Alzheimers Dement 2011;7:80-93.
41. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining? Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 2012;78:1456-1463.